Cancer treatment reviews最新文献

{"title":"Circulating tumour DNA in head and neck squamous-cell carcinomas: A literature review","authors":"Léo Ventelou ,&nbsp;Angeline Ginzac ,&nbsp;Marie-Céleste Ferreira ,&nbsp;Laurie Canetti ,&nbsp;Soline Philippe ,&nbsp;Céleste Pinard ,&nbsp;Xavier Durando ,&nbsp;Maureen Bernadach","doi":"10.1016/j.ctrv.2025.103070","DOIUrl":"10.1016/j.ctrv.2025.103070","url":null,"abstract":"<div><h3>Background</h3><div>In 60 % of cases, head and neck cancers (HNCs) are diagnosed at an advanced stage and therefore have a poor prognosis with survival rates of only 49 months. Circulating tumour DNA (ctDNA) has emerged as a minimally invasive biomarker able to improve early detection, assess minimal residual disease, monitor systemic treatment response and identify therapeutic targets. This literature review aims to critically synthesise evidence from the past decade on the clinical use of ctDNA in both HPV-related and HPV-unrelated HNCs.</div></div><div><h3>Patients and methods</h3><div>A literature review was performed using PubMed and Cochrane Library on March 11th 2024, updated on November 21st, 2025, using the keywords: “circulating tumour DNA”, “head and neck cancer”, “ctHPV-DNA associated with HNSCC”, “liquid biopsy and HNSCC”.</div></div><div><h3>Results</h3><div>After evaluation of 363 articles identified, 92 were included. ctDNA has been investigated for screening, diagnosis, prognostic stratification, treatment-response assessment, relapse detection and identification of therapeutic targets. However, performance varies considerably across studies due to methodological and biological heterogeneity.</div></div><div><h3>Conclusion</h3><div>ctDNA shows strong potential for response assessment and post-treatment monitoring, particularly in HPV-related disease. Nevertheless, its integration into clinical practice requires methodological standardisation and validation in larger prospective studies.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103070"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145822356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis”. [Cancer Treat Rev. 139 (2025) 102991. doi: 10.1016/j.ctrv.2025.102991]","authors":"Zoulikha M. Zaïr ,&nbsp;Gemma Butterworth ,&nbsp;Mariam Shalaby ,&nbsp;Eduard Oštarijaš ,&nbsp;Fiona Thistlethwaite","doi":"10.1016/j.ctrv.2025.103052","DOIUrl":"10.1016/j.ctrv.2025.103052","url":null,"abstract":"","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103052"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145643969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary tumor and metastasis-directed treatment for oligometastatic prostate cancer: An umbrella review of meta-analyses","authors":"Fausto Petrelli ,&nbsp;Francesca Trevisan ,&nbsp;Lorenza Bruschieri ,&nbsp;Valentina Riboldi ,&nbsp;Ivano Vavassori ,&nbsp;Silvia Seghezzi ,&nbsp;Andrea Esposito ,&nbsp;Lorenzo Dottorini ,&nbsp;Agostina De Stefani","doi":"10.1016/j.ctrv.2025.103064","DOIUrl":"10.1016/j.ctrv.2025.103064","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;The management of metastatic prostate cancer (mPC) has shifted from a purely systemic approach to an integrated paradigm incorporating local and metastasis-directed therapies. Advances in imaging and improved characterization of the &lt;em&gt;oligometastatic state&lt;/em&gt; have stimulated renewed interest in aggressive multimodal treatment strategies.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To systematically evaluate and grade the evidence from published &lt;em&gt;meta&lt;/em&gt;-analyses investigating the efficacy, safety, and credibility of local and metastasis-directed treatments in metastatic or oligometastatic prostate cancer.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design, setting, and participants&lt;/h3&gt;&lt;div&gt;This umbrella review followed PRISMA 2020 recommendations and Ioannidis umbrella-review methodology. PubMed, Embase, Web of Science, and Cochrane Library were searched through June 2025. Eligible studies were systematic reviews or &lt;em&gt;meta&lt;/em&gt;-analyses with quantitative pooling of outcomes for local treatment (LT; prostate radiotherapy [RT] or radical prostatectomy [RP]), cytoreductive radical prostatectomy (CRP), or metastasis-directed therapy (MDT) using stereotactic body radiotherapy (SBRT). Twenty-one &lt;em&gt;meta&lt;/em&gt;-analyses published between 2018 and 2025, enrolling &gt; 160 000 patients, were included.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Outcome measurements and statistical analysis&lt;/h3&gt;&lt;div&gt;Primary endpoints were overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS). Secondary endpoints included local control, toxicity, and prevention of symptomatic pelvic events. When multiple &lt;em&gt;meta&lt;/em&gt;-analyses assessed the same association, second-level pooling was performed. Evidence credibility was graded as &lt;em&gt;strong, highly suggestive, suggestive,&lt;/em&gt; or &lt;em&gt;weak.&lt;/em&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results and limitations&lt;/h3&gt;&lt;div&gt;Prostate RT improved OS in &lt;em&gt;low-volume metastatic hormone-sensitive disease&lt;/em&gt; (pooled HR ≈ 0.64–0.73) with minimal grade ≥ 3 toxicity (∼5%) and low heterogeneity (I&lt;sup&gt;2&lt;/sup&gt; ≈ 0 %). CRP demonstrated suggestive OS and CSS advantages (HR/OR ≈ 0.6–0.8; CSS ≈ 0.5) versus systemic therapy alone but no superiority over RT. MDT/SBRT significantly prolonged PFS (HR ≈ 0.48) and showed emerging OS benefit (HR ≈ 0.60) across randomized trials, with very low rates of serious toxicity (&lt;2%). Local therapy halved the risk of symptomatic pelvic complications (RR 0.50). Limitations include residual heterogeneity in imaging, disease definitions, and non-randomized data for surgical outcomes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Across 21 &lt;em&gt;meta&lt;/em&gt;-analyses, &lt;em&gt;prostate RT&lt;/em&gt; provides highly suggestive evidence of survival benefit in low-volume mHSPC, &lt;em&gt;CRP&lt;/em&gt; offers suggestive survival improvement in selected patients, and &lt;em&gt;MDT/SBRT&lt;/em&gt; achieves highly suggestive evidence for progression control with emerging OS benefit. These strategies represent validated, evidence-based components of modern mul","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103064"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145758363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors","authors":"Hassan Izzedine ,&nbsp;Rimda Wanchoo ,&nbsp;Ruby Sharma ,&nbsp;Kenar D. Jhaveri","doi":"10.1016/j.ctrv.2025.103060","DOIUrl":"10.1016/j.ctrv.2025.103060","url":null,"abstract":"<div><div>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (CDK4/6i) have emerged as a standard of care for hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, significantly improving patient survival. While generally well-tolerated, their use is associated with a spectrum of adverse events, particularly impacting renal, cardiovascular, and metabolic systems. Clinical data indicate a higher incidence of nephrotoxic adverse reactions in patients receiving CDK4/6i compared to control groups, with abemaciclib showing the highest risk ratio. These renal effects can manifest as true acute kidney injury (AKI), including rare cases of acute tubular injury and acute interstitial nephritis, or as a more common “pseudo-AKI.” The latter is characterized by an increase in serum creatinine due to the inhibition of renal organic cation transporters (OCT2/MATE), often without an actual decline in glomerular filtration rate (GFR). This highlights the importance of utilizing cystatin C alongside creatinine for accurate GFR assessment. Preclinical studies suggest a complex effect on renal health; while some data indicate acute nephroprotection, long-term rodent models treated with palbociclib after ischemic AKI demonstrated impaired recovery, increased renal fibrosis, and cellular senescence, indicating potentially detrimental long-term chronic effects. Beyond renal considerations, CDK4/6i are also associated with hypertension and electrolyte imbalance like hypokalemia and hyponatremia. Furthermore, these agents are susceptible to significant drug-drug interactions, particularly with CYP3A4 inhibitors/inducers and immunosuppressants, necessitating careful dose adjustments and monitoring, especially in solid organ transplant recipients. This review consolidates current evidence regarding the renal of CDK4/6i, emphasizing the need for vigilant monitoring and a multidisciplinary approach to optimize patient outcomes.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103060"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis","authors":"Alicia Escudero ,&nbsp;Meritxell Bellet ,&nbsp;Cristina Saura ,&nbsp;Anna Aguilera ,&nbsp;Andri Papakonstantinou ,&nbsp;Pablo Tolosa ,&nbsp;José Ángel García-Sáenz ,&nbsp;Fernando Moreno ,&nbsp;Alfonso López de Sá ,&nbsp;Francesco Schettini ,&nbsp;Elia Seguí ,&nbsp;Marta Gonzalez-Rodriguez ,&nbsp;Victor Navarro ,&nbsp;Juan Manuel Ferrero-Cafiero ,&nbsp;Xavier González ,&nbsp;Cristina Hernando ,&nbsp;Alexios Matikas ,&nbsp;Aleix Prat ,&nbsp;Mafalda Oliveira ,&nbsp;Tomas Pascual ,&nbsp;Guillermo Villacampa","doi":"10.1016/j.ctrv.2025.103063","DOIUrl":"10.1016/j.ctrv.2025.103063","url":null,"abstract":"<div><h3>Background</h3><div>Several endocrine-based strategies have been evaluated following CDK4/6 inhibition (CDK4/6i) in hormone receptor–positive advanced breast cancer. However, the absence of head-to-head comparisons leave uncertainty regarding the optimal treatment selection.</div></div><div><h3>Methods</h3><div>A systematic literature search was performed to identify randomized controlled trials (RCTs) evaluating endocrine-based strategies after CDK4/6i for hormone receptor-positive advanced breast cancer. A network <em>meta</em>-analysis was used to compare overall treatment strategies, rather than individual treatments. In addition, an extracted individual patient data <em>meta</em>-analysis was conducted. The primary endpoint was progression-free survival (PFS) evaluated independently in tumors with PI3K-AKT-PTEN alterations, <em>ESR1</em>-mutated and wild-type tumors.</div></div><div><h3>Results</h3><div>A total of 20 RCTs including 4,716 patients were included. In <em>ESR1</em>-mutated tumors, oral SERD/SERM/PROTAC showed numerically better PFS compared with switching CDK4/6i plus fulvestrant (HR = 0.67, 95 % CI 0.45–1.00). In this population, the addition of i) CDK4/6i or ii) mTORi to oral SERDs improved PFS compared with oral SERD/SERM/PROTAC alone (HR = 0.44, 95 % CI 0.27–0.72 and HR = 0.45, 95 % CI 0.23–0.89, respectively). In PI3K-AKT-PTEN altered tumors, the greatest benefit was observed with PI3K/AKT/mTORi plus fulvestrant and oral SERDs plus CDK4/6i (P-scores &gt; 0.75). In <em>ESR1</em> and PI3K/AKT/PTEN wild-type tumors, several treatment combinations outperformed fulvestrant. The use of PI3K/AKT/mTORi plus fulvestrant was associated with the highest incidence of grade ≥ 3 adverse events (66.0 %).</div></div><div><h3>Conclusion</h3><div>This <em>meta</em>-analysis reinforces the importance of molecular stratification in treatment decisions after CDK4/6i progression, highlighting the need for efficacy and safety assessments across biomarker-selected subgroups.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103063"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer – A systematic review and meta-analysis","authors":"Yee-Yin Hoo ,&nbsp;Wei-Wei Sia ,&nbsp;Sharminii Jaya-Prakason ,&nbsp;Bogda Koczwara ,&nbsp;Yek-Ching Kong ,&nbsp;Joe-Elie Salem ,&nbsp;Agnès Dechartres ,&nbsp;Nirmala Bhoo-Pathy","doi":"10.1016/j.ctrv.2025.103069","DOIUrl":"10.1016/j.ctrv.2025.103069","url":null,"abstract":"<div><h3>Background</h3><div>Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) improve survival in HR+/HER2- breast cancer, but agent-specific cardiotoxicity remains a concern. We evaluated the risk of QTc prolongation, and other cardiovascular adverse events (CVAEs) associated with ribociclib, palbociclib, and abemaciclib.</div></div><div><h3>Method</h3><div>We conducted a systematic review and meta-analysis (up to May 31st, 2025), assessing QTc prolongation and other CVAEs in patients with HR+/HER2- breast cancer receiving CDK4/6i plus endocrine therapy versus endocrine therapy alone<strong>.</strong> (PROSPERO: CRD42023460559; UICC Technical Fellowship (TF-20–716796).</div></div><div><h3>Results</h3><div>Twenty-three studies (22 RCTs, 1 cohort) were included. CDK4/6i increased the risk of grade 3/4 QTc prolongation (RR 1.83, 95% CI 1.23–2.74), driven by ribociclib (RR 1.95, 95% CI 1.27–2.98). Palbociclib showed no association, whereas no abemaciclib trials reported QTc data. VTE risk was elevated overall (RR 2.57, 95% CI 1.53–4.32), highest with abemaciclib (RR 5.14, 95% CI 3.09–8.54), while palbociclib was borderline (RR 2.13, 95% CI 0.99–4.57). Subgroup analyses revealed no consistent effect modifiers for ribociclib (QTc) or abemaciclib (VTE). No significant increase was observed for other composite CVAEs (RR 0.99, 95% CI 0.83–1.19) or for individual CVAEs. A hypothesis-generating signal for supraventricular arrhythmias was noted with abemaciclib (RR 3.87, 95% CI 1.19–12.53), based on sparse events. Heterogeneity was low across analyses.</div></div><div><h3>Conclusion</h3><div>Our findings mandate drug-tailored rather than class-wide cardiovascular monitoring in patients receiving CDK4/6i: ribociclib warrants routine ECG surveillance, abemaciclib requires intensified monitoring for VTE, and palbociclib shows no consistent signal but still merits vigilance.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103069"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145786439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis","authors":"Daniel G. Camblor ,&nbsp;Belén Martínez-Castedo ,&nbsp;Jorge Martín-Arana ,&nbsp;Francisco Gimeno-Valiente ,&nbsp;Blanca García-Micó ,&nbsp;Francisco Martínez-Picó ,&nbsp;Víctor Seguí ,&nbsp;Miguel García-Bartolomé ,&nbsp;Diego González ,&nbsp;Alejandro Guimera ,&nbsp;Marisol Huerta ,&nbsp;Susana Roselló ,&nbsp;Valentina Gambardella ,&nbsp;Desamparados Roda ,&nbsp;Leontios Pappas ,&nbsp;Aparna Parikh ,&nbsp;Juan Antonio Carbonell-Asins ,&nbsp;Andrés Cervantes ,&nbsp;Noelia Tarazona","doi":"10.1016/j.ctrv.2025.103066","DOIUrl":"10.1016/j.ctrv.2025.103066","url":null,"abstract":"<div><div>In patients with early-stage colorectal cancer (CRC), circulating tumor DNA (ctDNA) testing is increasingly used to detect minimal residual disease (MRD) after curative-intent surgery. This information can guide decisions on adjuvant chemotherapy and surveillance. Two main approaches exist, tumor-informed (TI) and tumor-agnostic (TA), however, their diagnostic accuracy in clinical practice remains unclear. We conducted a bivariate diagnostic meta-analysis to compare sensitivity and specificity of TI versus TA ctDNA assays for detecting recurrence in patients with resected CRC. Subgroup analyses were performed based on landmark versus serial sampling strategies. In the serial-sampling setting, TI assays demonstrated markedly higher sensitivity than TA assays (0.88 vs. 0.59; p = 0.001), with no significant differences in false-positive rates. The landmark analyses did not show statistically significant differences between approaches. The results underscore the importance of sampling strategy when selecting a ctDNA test. When longitudinal monitoring is feasible, TI assays provide the most reliable detection of recurrence. This meta-analysis supports tailoring ctDNA testing to the clinical context, prioritizing TI approaches for serial surveillance to better guide adjuvant decision-making and improve patient outcomes.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103066"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145770263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review","authors":"Luiz F. Costa de Almeida ,&nbsp;Luís Felipe Leite ,&nbsp;Anelise Poluboiarinov Cappellaro ,&nbsp;Lucas Diniz da Conceição ,&nbsp;Mariana Macambira Noronha ,&nbsp;Jessé Lopes da Silva ,&nbsp;Andreia Cristina de Melo ,&nbsp;Felipe Batalini ,&nbsp;Paolo Tarantino","doi":"10.1016/j.ctrv.2025.103067","DOIUrl":"10.1016/j.ctrv.2025.103067","url":null,"abstract":"<div><h3>Background</h3><div>Antibody–drug conjugates (ADCs) have redefined the treatment landscape of metastatic breast cancer (mBC), offering durable responses across all subtypes. As multiple ADCs with similar payloads become available for the same patient over the course of the disease, determining the optimal sequencing strategy has become an urgent need, particularly given concerns about cross-resistance and reduced efficacy.</div></div><div><h3>Methods</h3><div>A literature search identified 1868 citations, of which 23 studies (n = 2934 patients) met the inclusion criteria, encompassing ten full-text publications and 13 abstracts. Data on clinical subtypes, sequencing strategies, efficacy outcomes, and real-world evidence (RWE) were extracted and analyzed.</div></div><div><h3>Results</h3><div>In HER2-low mBC, initial ADC exposure produced higher response rates and longer PFS than subsequent ADCs, with median PFS declining from 5.1–7.6 months to 2.1–3.1 months and OS from 16.5–22.8 months to 5.6–8.0 months. In HER2-positive disease, clinical activity was partially preserved with the second ADC, particularly when T-DXd followed T-DM1, with sustained PFS. TNBC and HR+/HER2– cohorts showed a consistent decline in efficacy with second ADC exposure (PFS 2.5–3.1 months). Evidence indicates that switching ADC payloads mitigates cross-resistance, with improved ORR and PFS2 compared to same-payload sequences. Bridging chemotherapy between ADCs did not compromise efficacy and, in some cohorts, yielded a longer PFS than direct sequencing with another ADC with the same payload.</div></div><div><h3>Conclusion</h3><div>Emerging evidence indicates that sequential ADC use can be effective despite some cross-resistance, especially when distinct payload mechanisms are employed. Clinical use should consider payload type, timing, and breast cancer subtype, but toxicities remain critical for decision-making. Research providing insights into resistance mechanisms and biomarkers is needed for personalized approaches.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103067"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145770305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer","authors":"Claire Lin ,&nbsp;Matthew J. Hadfield ,&nbsp;Amol Rathore ,&nbsp;Maximilian Pinho-Schwermann ,&nbsp;Shengliang Zhang ,&nbsp;Shaolei Lu ,&nbsp;Petra den Hollander ,&nbsp;Sendurai A. Mani ,&nbsp;Attila A. Seyhan ,&nbsp;Ariana Santopietro ,&nbsp;Anthony Mega ,&nbsp;Liang Cheng ,&nbsp;Wafik S. El-Deiry ,&nbsp;Benedito A. Carneiro","doi":"10.1016/j.ctrv.2025.103061","DOIUrl":"10.1016/j.ctrv.2025.103061","url":null,"abstract":"<div><div>Prostate cancer (PCa) is a leading cause of cancer-related morbidity and mortality. Despite the efficacy of androgen deprivation therapy (ADT), patients with advanced PCa eventually progress to a lethal castration-resistant disease state. Cellular senescence represents a stable growth arrest induced by stress signaling cascades or cancer therapeutics, and escape from a senescent state may be implicated in the development of castration resistance. We discuss the mechanisms promoting cellular senescence in PCa and its contribution to therapeutic resistance to ADT, PARP inhibitors, chemotherapy, and radiation. We also summarize the potential of senolytic and senomorphic therapies in targeting senescent prostate cancer cells in the setting of therapy-induced senescence.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103061"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145662886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone metastases in NSCLC: Modern paradigms in management and supportive care","authors":"Gabriele Minuti ,&nbsp;Giorgia Pasqualini ,&nbsp;Alice Avancini ,&nbsp;Niccolò Giaj-Levra ,&nbsp;Francesca Colonese ,&nbsp;Alessandro Di Federico ,&nbsp;Alessandra Fozza ,&nbsp;Michele Montrone ,&nbsp;Emanuela Olmetto ,&nbsp;Edoardo Pastorello ,&nbsp;Maria Lucia Reale ,&nbsp;Silvia Teresa Riva ,&nbsp;Elisa Roca ,&nbsp;Claudio Sini ,&nbsp;Giuseppe Viscardi ,&nbsp;Sara Pilotto ,&nbsp;Francesco Passiglia","doi":"10.1016/j.ctrv.2025.103051","DOIUrl":"10.1016/j.ctrv.2025.103051","url":null,"abstract":"<div><div>Bone metastases (BoMs) are a frequent complication in advanced non-small-cell lung cancer (NSCLC), affecting approximately one third of patients at diagnosis and 35–60 % during the disease course. BoMs increase the risk of skeletal-related events (SREs), which have a detrimental impact on prognosis, performance status, and quality of life (QoL). Management of BoMs in NSCLC requires a multimodal approach. Although systemic anti-cancer therapies remain the cornerstone, the optimal management of BoMs in NSCLC also encompasses bone-targeted agents (BTAs) such as bisphosphonates and denosumab, local treatments including radiotherapy and surgical interventions, and supportive care strategies aimed at preventing SREs, alleviating pain, preserving mobility, and maintaining QoL. This review provides an updated overview of best practices for managing BoMs in NSCLC, covering diagnostic work‑up, therapeutic strategies, and the growing role of multidisciplinary care. It emphasizes the importance of supportive interventions, including nutrition and physical activity, to optimize outcomes in the era of targeted and immune-based therapies, alongside comprehensive simultaneous care.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103051"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}